4-nitrobenzyl (7R,8S)-8-[(1R)-1-(tert-butyldimethylsilyloxy)ethyl]-5,9-dioxo-1-azabicyclo[5.2.0]non-2-ene-2-carboxylate | 180535-01-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-nitrobenzyl (7R,8S)-8-[(1R)-1-(tert-butyldimethylsilyloxy)ethyl]-5,9-dioxo-1-azabicyclo[5.2.0]non-2-ene-2-carboxylate
• 英文别名: 4-nitrobenzyl (7R,8S)-8-[(1R)-1-(tert-butyldimethylsilyloxy)-ethyl]-5,9-dioxo-1-azabicyclo[5.2.0]non-2-ene-2-carboxylate；(4-nitrophenyl)methyl (7R,8S)-8-[(1R)-1-[tert-butyl(dimethyl)silyl]oxyethyl]-5,9-dioxo-1-azabicyclo[5.2.0]non-2-ene-2-carboxylate
• CAS: 180535-01-7
• 化学式: C₂₄H₃₂N₂O₇Si
• 分子量: 488.613
• InChiKey: APQZHYVMFCKORJ-IPHXSNPTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.12
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  119
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-nitrobenzyl (7R,8S)-8-[(1R)-1-(tert-butyldimethylsilyloxy)ethyl]-5,9-dioxo-1-azabicyclo[5.2.0]non-2-ene-2-carboxylate 生成 4-Nitrobenzyl (7R,8S)-8-[(1R)-1-(tert-butyldimethylsilyloxy)ethyl]-5-[2-(4-nitrobenzyloxycarbonyl)-aminoethylthio]-9-oxo-1-azabicyclo[5.2.0]non-2,4-diene-2-carboxylate
  参考文献：
  名称：

  9-oxo-1-azabicyclo\x9b5.2.0!non-2,4-diene-2-carboxylic acid compounds as

  摘要：

  本发明提供了化合物的公式(I)：##STR1##其中R.sup.1是氢，可选地取代的；酰胺基，C.sub.1-6烷基，C.sub.2-6烯基，C.sub.2-6炔基，C.sub.1-6烷氧基，C.sub.1-6烷酰氧基，C.sub.1-6烷基氨基，二-(C.sub.1-6烷基)氨基，C.sub.1-6烷氧羰基，氨基羰基，C.sub.1-6烷基氨基羰基或二-(C.sub.1-6烷基)氨基羰基；R.sup.2是氢或C.sub.1-6烷氧基；或R.sup.1和R.sup.2一起形成可选取代的C.sub.1-6烷基；R.sup.3和R.sup.5独立地是氢或C.sub.1-6烷基；R.sup.4和R.sup.6中的一个是氢或C.sub.1-4烷基，另一个被选择自多个基团或其药学上可接受的盐或体内水解酯。它们的制备方法，制备中间体，作为治疗剂的用途以及含有它们的药物组合物。

  公开号：

  US05719139A1

文献信息

• 9-oxo-1-azabicyclo\x9b5.2.0!non-2,4-diene-2-carboxylic acid compounds as
  申请人：Zeneca Limited

  公开号：US05719139A1

  公开（公告）日：1998-02-17

  The present invention provides a compound of the formula (I): ##STR1## wherein R.sup.1 is hydrogen, optionally substituted; acylamino, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 alkoxy, C.sub.1-6 alkanoyloxy, C.sub.1-6 alkylamino, di-(C.sub.1-6 alkyl)amino, C.sub.1-6 alkoxycarbonyl, aminocarbonyl, C.sub.1-6 alkylaminocarbonyl or di-(C.sub.1-6 alkyl)aminocarbonyl; R.sup.2 is hydrogen or C.sub.1-6 alkoxy; or R.sup.1 and R.sup.2 together form optionally substituted C.sub.1-6 alkylene; R.sup.3 and R.sup.5 are independently hydrogen or C.sub.1-6 alkyl; and one of R.sup.4 and R.sup.6 is hydrogen or C.sub.1-4 alkyl and the other is selected from a number of groups or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof. Processes of their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.

  本发明提供了化合物的公式(I)：##STR1##其中R.sup.1是氢，可选地取代的；酰胺基，C.sub.1-6烷基，C.sub.2-6烯基，C.sub.2-6炔基，C.sub.1-6烷氧基，C.sub.1-6烷酰氧基，C.sub.1-6烷基氨基，二-(C.sub.1-6烷基)氨基，C.sub.1-6烷氧羰基，氨基羰基，C.sub.1-6烷基氨基羰基或二-(C.sub.1-6烷基)氨基羰基；R.sup.2是氢或C.sub.1-6烷氧基；或R.sup.1和R.sup.2一起形成可选取代的C.sub.1-6烷基；R.sup.3和R.sup.5独立地是氢或C.sub.1-6烷基；R.sup.4和R.sup.6中的一个是氢或C.sub.1-4烷基，另一个被选择自多个基团或其药学上可接受的盐或体内水解酯。它们的制备方法，制备中间体，作为治疗剂的用途以及含有它们的药物组合物。